Compare State Street SPDR S&P Biotech ETF (XBI) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Yum China Holdings Inc — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.8, while Yum China Holdings Inc trades at $42.32 (market cap $14.74B). The key difference: Yum China Holdings Inc pays a 2.68% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Yum China Holdings Inc nearer its low. Which is the better fit depends on your goals.
| XBI | YUMC | |
|---|---|---|
Sector | Broad Market / Factor | Consumer Cyclical |
52-Week High | $169.55 | $57.95 |
52-Week Low | $93.43 | $40.18 |
Market Cap | — | $14.74B |
Enterprise Value | — | $15.65B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
YUMC trades at $43.34, down 0.6% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth, reaching $11.8B in 2025, with a net income margin of 7.84%. Recent developments include the acquisition of Pizza Hut brand ownership in Mainland China and expansion of Pizza Hut Burger Bars to 300 locations.
The outlook is positive with strong analyst support—14 buy ratings and a projected 25.6% upside. Risks include competitive pressures and market volatility, but solid fundamentals and growth initiatives provide a compelling case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
